THE EFFECT OF GARCINIA CAMBOGIA AS COADJUVANT IN THE WEIGHT LOSS PROCESS
Patricia Fassina1, Fernanda Scherer Adami2, Valdeni Terezinha Zani2
1Faculdade de Nutrição, Centro de Ciências Biológicas e da Saúde, Centro Universitário UNIVATES, Universitário, Lajeado, Rio Grande do Sul.. simonedb@ufcspa.edu.br.
Nutricion Hospitalaria
|December 16, 2015
Summary
Garcinia Cambogia (GC) shows potential for weight loss and appetite reduction, but its effectiveness varies. Further research is needed to establish optimal dosage and confirm its efficacy as a natural obesity treatment.
Area of Science:
- Nutritional Science
- Pharmacology
- Public Health
Background:
- Rising global obesity rates present a significant public health challenge.
- Natural herbal products are increasingly explored for safer obesity treatment options.
- Garcinia Cambogia (GC) extract is a popular natural supplement for weight management.
Purpose of the Study:
- To evaluate Garcinia Cambogia (GC) as an adjunct therapy for obesity.
- To investigate GC's efficacy, mechanism of action, dosage, side effects, and contraindications.
- To assess GC's role in food and nutritional security.
Main Methods:
- Comprehensive literature review of studies from 2007-2014.
- Databases searched: LILACS-BIREME, SciELO, MEDLINE.
- Keywords: Garcinia Cambogia, weight loss, obesity, Hydroxycitric Acid (HCA).
Main Results:
- Some studies indicate GC aids weight loss, reduces appetite, and lowers body fat percentage.
- Observed effects include improvements in triglyceride, cholesterol, and glucose levels.
- Other studies reported no significant effects of GC.
Conclusions:
- Evidence suggests GC may be effective for weight loss.
- Optimal dosage and long-term efficacy require further investigation.
- Limited adverse effects noted; potential hepatoprotective properties observed.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
379
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
379
01:21Drug Dosing: Obese Patients
339
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
339
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
281
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
281
01:24Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
01:28Adrenergic Agonists: Mixed-Action Agents
1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K